Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician
- PMID: 26177314
- DOI: 10.5146/tjpath.2015.01311
Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician
Abstract
Pituitary adenomas comprise a heterogenous group of adenohypophyseal tumours with distinct clinicopathological features across both the clinically functioning and silent groups. Although, predicting a clinically aggressive course remains challenging, accurate subtyping of pituitary adenomas offers valuable prognostic information that together with other clinical and radiological information serves as a platform for tailored treatment and follow-up. For instance, silent subtype 3 pituitary adenomas, silent corticotroph adenomas, acidophil stem cell adenomas, Crooke cell adenomas, and sparsely granulated somatotroph adenomas show more invasive growth. This review has been formulated as a set of practical questions that address the distinct clinical behaviour of a selected group of pituitary adenoma subtypes.
Similar articles
-
Overview of the 2017 WHO Classification of Pituitary Tumors.Endocr Pathol. 2017 Sep;28(3):228-243. doi: 10.1007/s12022-017-9498-z. Endocr Pathol. 2017. PMID: 28766057 Review.
-
Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.Mod Pathol. 2016 Feb;29(2):131-42. doi: 10.1038/modpathol.2015.151. Epub 2016 Jan 8. Mod Pathol. 2016. PMID: 26743473
-
Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.Eur J Endocrinol. 2007 Feb;156(2):203-16. doi: 10.1530/eje.1.02326. Eur J Endocrinol. 2007. PMID: 17287410 Review.
-
Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently.Clin Endocrinol (Oxf). 2003 Jan;58(1):59-64. doi: 10.1046/j.1365-2265.2003.01674.x. Clin Endocrinol (Oxf). 2003. PMID: 12519413
-
Clinicopathologic correlates of giant pituitary adenomas.J Clin Neurosci. 2009 May;16(5):660-5. doi: 10.1016/j.jocn.2008.08.018. Epub 2009 Mar 12. J Clin Neurosci. 2009. PMID: 19285407 Clinical Trial.
Cited by
-
Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.Pituitary. 2017 Feb;20(1):84-92. doi: 10.1007/s11102-016-0748-8. Pituitary. 2017. PMID: 27586499 Review.
-
Overview of the 2017 WHO Classification of Pituitary Tumors.Endocr Pathol. 2017 Sep;28(3):228-243. doi: 10.1007/s12022-017-9498-z. Endocr Pathol. 2017. PMID: 28766057 Review.
-
[Unification of pathomorphological examination of patients with neuroendocrine tumors of the pituitary gland. Controversial issues of the new classification].Probl Endokrinol (Mosk). 2023 Nov 14;70(3):31-45. doi: 10.14341/probl13376. Probl Endokrinol (Mosk). 2023. PMID: 39069771 Free PMC article. Review. Russian.
-
Clinical and Pathological Aspects of Silent Pituitary Adenomas.J Clin Endocrinol Metab. 2019 Jul 1;104(7):2473-2489. doi: 10.1210/jc.2018-00688. J Clin Endocrinol Metab. 2019. PMID: 30020466 Free PMC article. Review.
-
Increased expression of the microRNA 106b~25 cluster and its host gene MCM7 in corticotroph pituitary adenomas is associated with tumor invasion and Crooke's cell morphology.Pituitary. 2017 Aug;20(4):450-463. doi: 10.1007/s11102-017-0805-y. Pituitary. 2017. PMID: 28432562 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical